108.
To evaluate the safety and efficacy of pegfilgrastim administered as haematological support after autologous peripheral blood
stem cell transplantation, we compared 44 patients with solid tumours and lymphomas receiving a 6-mg single dose of pegfilgrastim
on day +5 after transplantation to a historical control group of 25 patients receiving filgrastim 5 μg kg
−1 day
−1 starting on day +5. There were no significant differences in haematological recovery nor in the incidence and duration of
neutropenic fever. Median duration of grade 4 neutropenia in the pegfilgrastim and filgrastim group was similar. The incidence
of grade III–IV mucositis was lower in pegfilgrastim than in filgrastim group due to the significant difference observed among
the patients with solid tumours (
p = 0.00). The only adverse event considered to be cytokine related was mild to moderate bone pain occurring during haematological
recovery. According to the present study design and taking into account the current prices in our institution, the cost of
the two drugs was similar in both treatment groups. In conclusion, a single injection of pegfilgrastim administered at day
+5 post-transplantation shows comparable safety and efficacy profiles to daily injections of filgrastim and may be cost effective.
Alberto Ballestrero and Davide Boy contributed equally to this article.
相似文献